Results for FF/UMEC/VI compared with FF/VI or UMEC/VI base case ITT population and NICE recommended subgroup
| FF/UMEC/VI | FF/VI | Incremental (FF/UMEC/VI versus FF/VI) | UMEC/VI | Incremental (FF/UMEC/VI versus UMEC/VI) | |
| Base case ITT population | |||||
| Predicted exacerbations | |||||
| Moderate exacerbations | 5.712 | 5.799 | –0.087 | 5.888 | –0.176 |
| Severe exacerbations | 1.371 | 1.378 | –0.007 | 1.420 | –0.049 |
| Any moderate and/or severe exacerbation | 7.083 | 7.177 | –0.094 | 7.309 | –0.225 |
| Total LYs (discounted) | 8.874 | 8.577 | 0.296 (0.198–0.399) | 8.728 | 0.145 (0.041–0.253) |
| Total QALYs | 6.564 | 6.289 | 0.275 (0.033–0.512) | 6.446 | 0.118 (–0.124–0.355) |
| Costs | |||||
| Maintenance | £7926 | £8479 | –£552 | £8030 | –£104 |
| Moderate exacerbations | £2666 | £2738 | –£72 | £2776 | –£110 |
| Severe exacerbations | £6827 | £6929 | –£102 | £7154 | –£327 |
| Pneumonia | £963 | £940 | £22 | £606 | £357 |
| Treatment | £3881 | £1759 | £2122 | £2546 | £1335 |
| Replacement therapy | £806 | £1095 | –£290 | £1197 | –£392 |
| Total costs | £23 069 | £21 941 | £1129 (£683–£1533) | £22 310 | £760 (£305–£1165) |
| ICER per LY gained | £3809 (£2199–£6177) | £5225 (£1704–£19 702) | |||
| ICER per QALY gained | £4104 (£1646–£19 201) | £6418 (dominant, £65 705) | |||
| Patients with ≥2 moderate or ≥1 severe exacerbation in the previous year | |||||
| Predicted exacerbations | |||||
| Moderate exacerbations | 5.784 | 5.862 | –0.078 | 5.983 | –0.199 |
| Severe exacerbations | 1.384 | 1.396 | –0.012 | 1.464 | –0.080 |
| Any moderate and/or severe exacerbation | 7.168 | 7.258 | –0.090 | 7.447 | –0.279 |
| Total LYs (discounted) | 9.142 | 8.895 | 0.247 (0.148–0.356) | 8.996 | 0.146 (0.029–0.266) |
| Total QALYs | 6.800 | 6.571 | 0.229 (−0.013–0.473) | 6.686 | 0.114 (−0.134–0.365) |
| Costs | |||||
| Maintenance | £7468 | £7942 | –£474 | £7562 | –£94 |
| Moderate exacerbations | £2688 | £2750 | –£62 | £2811 | –£123 |
| Severe exacerbations | £6856 | £6978 | –£122 | £7369 | –£514 |
| Pneumonia | £1012 | £965 | £47 | £640 | £371 |
| Treatment | £4026 | £1843 | £2183 | £2624 | £1402 |
| Replacement therapy | £806 | £1084 | –£278 | £1222 | –£417 |
| Total costs | £22 855 | £21 562 | £1293 (£873–£1686) | £22 228 | £627 (£122–£1076) |
| ICER per LY gained | £5235 (£2997–£9662) | £4289 (£524–£21 488) | |||
| ICER per QALY gained | £5642 (dominant, £37 302) | £5495 (dominant, £61 459) |
Outcomes and costs observed over the complete period (trial-based and Markov models). All ranges are 95% confidence intervals, unless otherwise stated. 95% confidence intervals were derived from the probabilistic sensitivity analysis. FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; ITT: intention-to-treat; NICE: National Institute for Health and Care Excellence; LY: life year; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio.